Logo
MyCEI Login

Course

Highlights from the 24th International AIDS Conference: Montreal 2022

Details

Published Date: 10/07/2022

Expiration Date: 08/16/2025

CE Credit: CME:1

Presenter(s)

W. David Hardy,MD

W. David Hardy, MD, is a scientific and medical consultant focusing on developing novel vaccine and cure/remission strategies for human viral diseases. He serves as Adjunct Clinical Professor of Medicine at the Keck School of Medicine of USC. He served as Senior Director of Research at Whitman-Walker Health (Washington, DC) overseeing NIH-funded ACTG trials and HIV Cohort studies and industry-sponsored trials from 2015-2018. While there he held an academic appointment as Adjunct Professor of Medicine at Johns Hopkins University School of Medicine, Baltimore, Maryland. From 2002 to 2013 he served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. Dr. Hardy also served as chief medical officer for Calimmune (2013-2015), a small California-based biotechnology company, funded by the California Institute for Regenerative Medicine (CIRM), using gene-modified CD4+ T cells and hematopoietic stem cells as a potential cure for HIV infection.

He received his medical degree from Baylor College of Medicine, Houston, TX and completed his residency in internal medicine at Harbor-UCLA Medical Center in Torrance, California. Early in the AIDS epidemic, he completed a clinical fellowship in infectious diseases/immunology and clinical research at the UCLA School of Medicine under the direction of Dr. Michael Gottlieb, the physician who recognized and reported the first cases of AIDS. He also completed a laboratory fellowship in molecular retrovirology with Irvin Chen, PhD at the David Geffen School of Medicine at UCLA focusing on development of retroviral vector delivery of gene therapy and vaccine applications.

Dr. Hardy has cared for persons with HIV infection since 1982 and conducted research on HIV and related diseases since 1984. His research has focused on treatment and prevention of opportunistic infections, antiretroviral therapy, immunotherapies, hepatitis treatments as well as retroviral vector research, cellular and gene therapy as strategies for cure of HIV infection. Dr Hardy served as Chair of the Board of Directors of the HIV Medicine Association (HIVMA) 2018-2019. Currently, he serves as Chair of the Education Committee and member of the Executive Committee of the American Academy of HIV Medicine (AAHIVM). He has served as editor-in-chief of AAHIVM’s comprehensive clinical textbook, Fundamentals of HIV Medicine for the HIV Specialist published in 2007, 2008, 2012, 2017, 2019 and 2021. He has volunteered with several community-based organizations, including AIDS Research Alliance, the Alliance for Housing and Healing, Being Alive-Empowering People with HIV/AIDS, Project Angel Food, AIDS Project-Los Angeles and the Foundation for the AIDS Monument.



Learning Objectives

  • Be able to discuss new clinically relevant advances in antiretroviral therapy and prevention strategies for HIV.
  • Learn about new drugs for HIV treatment and prevention.
  • Recognize emerging adverse effects including metabolic effects associated with antiretrovirals used for treatment and prevention of HIV

Continuing Education Credit Information